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Abstract
Liver cancer is the predominant cause of cancer mortality in males of Southern China and Taiwan.
The current therapy is not satisfactory, and more effective treatments are needed. In the search
for new therapies for liver tumor, we found that Concanavalin A (Con A), a lectin from Jack bean
seeds, can have a potent anti-hepatoma effect. Con A after binding to the mannose moiety on the
cell membrane glycoprotein is internalized preferentially to the mitochondria. An autophagy is
triggered which leads to cell death. Con A as a T cell mitogen subsequently activates the immune
response in the liver and results in the eradication of the tumor in a murine in situ hepatoma model.
The liver tumor nodule formation is inhibited by the CD8+ T cells, and a tumor antigen-specific
immune memory is established during the hepatic inflammation. The dual properties (autophagic
cytotoxicity and immunomodulation) via the specific carbohydrate binding let Con A exert a potent
anti-hepatoma therapeutic effect. The novel mechanism of the Con A anti-hepatoma effect is
discussed. The prototype of Con with an anti-hepatoma activity gives support to the search for
other natural lectins as anti-cancer compounds.
Review
Liver cancer and hepatocarcinogenesis
Liver cancer is the fifth most important cancer worldwide,
and is the third most common cause of cancer mortality
because of the very poor prognosis [1]. Most liver cancers
are hepatocellular carcinomas (HCC) which have unique
epidemiologic features with dynamic temporal trends,
variations in different geographic regions, racial and eth-
nic group, sex, and risk factors. The highest incidence rates
are in Africa and eastern Asia. China alone accounts for
more than 50% of the world's cases. Incidence is low in
most developed countries, except for Japan, while a mod-
erately increased incidence occurs in southern European
countries. The major risk factors for HCC are chronic
infection with the hepatitis B (HBV) and C (HCV) virus,
although aflatoxins are thought to be an environmental
factor in tropical areas due to the contamination of food
with fungus. In Asia, the dominant risk factor is chronic
HBV infection that is largely acquired by maternal-child
transmission. However, in Japan or in Western countries,
the dominant hepatitis virus is HCV [2,3]. Individuals
who are chronic carriers of HBV have a greater than 100-
fold increased relative risk of developing a tumor. The uni-
versal immunization of infants with the HBsAg vaccine
not only decreases the HBV carrier rate, but also reduces
the incidence and mortality rate from HCC in Taiwanese
children [4]. Chronic active hepatitis is recognized as the
major risk factor for HCC, and is accompanied by liver cell
necrosis, inflammation, cytokine abnormal synthesis and
fibrosis. In Asia, America and Europe, 90% of HCC cases
are associated with cirrhosis. Three steps (hepatitis, cirrho-
sis, hepatocarcinogenesis) are involved in the evolution of
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HCC tumor formation post HBV/HCV chronic infection
[5].
The most common condition associated with hepatocar-
cinogenesis is cirrhosis, which develops after a latency of
20–40 years of chronic liver disease. HCC risk remains
low during chronic liver disease but exponentially
increases at the cirrhosis stage, suggesting that important
events precipitate the increase in liver tumor formation at
the cirrhosis stage. Liver cell proliferation is increased dur-
ing chronic hepatitis, but cirrhosis is characterized by
decreasing hepatocyte proliferation, indicating that the
regenerative capacity of the liver is exhausted at the cirrho-
sis stage. Both cell-intrinsic and cell-extrinsic alterations
are responsible for the cirrhosis-associated hepatocarcino-
genesis [5]. Telomere shorting is suggested to explain the
limited regenerative reserve of liver cells. Telomere short-
ing not only leads to an activation of the cell cycle and
apoptosis checkpoints that restrain the proliferative
capacity of liver cells and in turn select for hepatocytes car-
rying deletions of checkpoint genes, but also induces
chromosomal instability, which can accelerate the further
loss of the checkpoint function. Cirrhosis also causes
alterations of the liver environment by altering the
cytokine secretion from activated stellate cells as well as
inflammatory signaling from infiltrating immune cells.
Furthermore, the decrease in liver function at the cirrhosis
stage could increase toxic metabolites in the blood serum,
inducing alteration of the macroenvironment. The altered
milieu of both microenvironment (local factors in the
liver) and the macroenvironment (systemic acting factors)
could stimulate the impaired hepatocyte proliferation at
the cirrhosis stage, leading to a further selection of genet-
ically altered pre-malignant clone of transformed hepato-
cytes and then tumor formation.
Abnormal glycosylation on tumor cells and lectins
Glycoconjugates, consisting of large glycoproteins, play
an important protective role in many biological phenom-
ena [6]. The number of complex N-glycan and degree of
branching cooperate to regulate cell proliferation and dif-
ferentiation. Growth factor receptors have high numbers
of N-glycans and, therefore high avidities for the galectin
lattice. The surface levels of glycoprotein expression will
determine the transition between cell growth and arrest
[7,8]. An altered glycosylation of functionally important
membrane glycoproteins would affect tumor cell adhe-
sion or motility, resulting in invasion and metastasis. For
example, aberrant sialylation in cancer cells is found to
associate with malignant properties of invasiveness and
metastasis. Carbohydrate antigen sialyl Lewis a (CA19-9)
is used as a serum tumor marker for diagnosis of cancers
in the digestive organs. A high expression of sialoglyco-
conjugates in colorectal cancer is significantly associated
with poor prognosis and lymph node metastasis [9].
Lectins were previously used to define agglutinins that
could discriminate among types of red blood cells, but
now the term is used more generally to include sugar-
binding proteins from many source regardless of their
ability to agglutinate cells. Lectins have been found in
plant, viruses, microorganisms and animals. They have
been classified according to their sugar-binding specifi-
city. For example, Concanavalin A (Con A), Lens Culinaris
Agglutinin (LCA), and Pisum Sativum Agglutinin (PSA)
have specificity for glucose; Con A, LCA, Narcissus Pseu-
donarcissus (NPA), and PSA have specificity for mannose.
Most lectins are multimeric, consisting of non-covalently
associated subunits, can be homologous identical units or
heterologous different subunits. It is this multimeric struc-
ture that gives lectins the ability to agglutinate cells or
form aggregates with glycoconjugates in a manner similar
to the antigen-antibody complex. Although most lectins
can agglutinate some cell types, cellular agglutination is
not a prerequisite. Some lectins can bind to cells, but
would not cause agglutination. Another important char-
acteristics of some lectins is their ability to induce mitosis
in cells which are normally not dividing. Con A and PHA-
L have been used by immunologists as mitogens to stim-
ulate T cell blastogenesis. Lectins are also used as tools in
biochemistry, cell biology, and immunology, and have
also been used for diagnostic and therapeutic purposes in
cancer research [10-13]. The reversible bindings with free
sugars or with sugar residues of polysaccharides, glycopro-
teins, or glycolipids behave like the antibody and antigen
interaction, and are used for glycoprotein purification,
oligosaccharide analysis, and cell identification or enrich-
ment. Tumor cells have abnormal expression of lectins.
The level of cell surface lectins increases after normal cells
are transformed by oncogenes. Tumor cells exhibiting
metastatic propensity have higher levels of surface lectins.
The tumor cell surface lectins might be involved in cell-
cell adhesion, cell attachment to substratum, anchorage-
independent growth, and blood-borne metastasis. Malig-
nant transformation is associated with various and com-
plex alterations in the glycosylation process. The lectin-
cell surface carbohydrate interactions participate in the
process of metastasis. Cell surface carbohydrates affect
tumor cell interactions with normal cells or with the extra-
cellular matrix during metastatic spread and growth that is
mediated by tumor cell carbohydrates and their binding
proteins known as endogenous lectins. Cell glycosylation
depends on the expression and function of various glyco-
syltransferases and glycosidases. Changes of these
enzymes in malignant transformation indicate that cell
surface carbohydrates affect the metastatic behavior of
tumor cells. Some of these changes might provide a selec-
tive advantage for tumor cells during their progression to
more invasive and metastatic phenotypes. Lectins have
been used as tools for diagnosis and therapeutics, andJournal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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their anti-hepatoma effect involving autophagy will be
discussed below.
Autophagy and cancer
Autophagy is an evolutionarily conserved catabolic proc-
ess that degrades long-lived proteins, organelles, and bulk
cytoplasm [14-16]. The word "autophagy" is derived from
the Greek and means to eat (phagy) oneself (auto). Two
types of autophagy with dynamic rearrangement of the
sequestering membrane in eukaryotic cells are identified:
microautophagy and macroautophagy. They differ with
respect to the pathway by which cytoplasmic materials are
delivered to the lysosome, but share in common the final
steps of lysosomal degradation of the cargo with eventual
recycling of the degraded materials. Microautophagy is
the engulfment of cytoplasm directly at the lysosomal sur-
face while macroautophagy involves the formation of the
cytosolic double-membrane vesicles that sequester por-
tions of the cytoplasm or organelles. Fusion of the
autophagosome vesicle with the lysosome results in the
delivery of autophagic body into the lumen of the degra-
dative compartment and recycling of the nutrients. The
autophagy is usually referred to macroautophagy. It
occurs as a cellular response to both extracellular stress
conditions such as nutrient starvation, hypoxia, over-
crowding, heat, drug treatment, and intracellular stress
conditions such as accumulation of damage, superfluous
organelles and cytoplasmic components, and reactive
oxygen intermediates. In mammals, autophagy partici-
pates in many physiological processes, including the
response to starvation, cell growth control, anti-aging
mechanism, innate immunity, and antigen presentation.
Pathologically, the deregulation of autophagy is known to
play a role in diseases such as cancer, cardiomyopathy,
muscular diseases, and neurodegenerative disorders.
Autophagy is a dynamic, multi-step process that can be
modulated either positively or negatively [17]. An accu-
mulation of autophagosomes can result from a combina-
tion of increased autophagic activity and/or a reduced
turnover of autophagosomes. Autophagy induction
should be differentiated from autophagic flux, a complete
process of autophagy from the delivery of cargo to lyso-
somes and its subsequent breakdown and recycling.
Autophagy induction begins with an initiation of phago-
phore and sequestering the compartment into the
autophagosome. A defect in autophagosome turnover
may be due to a block in the fusion with lysosomes or dis-
ruption of lysosomal functions that results in increased
numbers of autophagosome. In this case, an autophagy is
induced, but there is no or limited autophagic flux. The
incomplete autophagy with the accumulation of
autophagosomes contributes to physiological dysfunc-
tion. In contrast, complete autophagy will generally exert
a cytoprotective effect.
Apoptosis (self-killing) and autophagy (self-eating) are
referred to as programmed cell death type I and type II,
respectively. Autophagy constitutes a stress adaptation
that avoids cell death, whereas in certain conditions,
autophagy will lead to an alternative cellular demise that
is called autophagic cell death (or type II cell death).
Apoptosis is characterized by caspase activation, DNA
fragmentation, cytoplasmic blebbing, and engulfment of
the apoptotic cell body by other phagocytes. In contrast,
cells that die with an autophagic cell death are capable of
digesting their own contents without the aid of engulfing
phagocytes, in a process that is usually caspase-independ-
ent. The morphological hallmark of autophagic cell death
is defined by the presence of autophagosomes and
autolysosomes in dying cells. The relationship between
apoptosis and autophagy is complex. Autophagy and
apoptosis may be triggered by common stimuli, and
sometimes results in combined autophagy and apoptosis.
In other instances, autophagy and apoptosis develop in a
mutually exclusive manner, perhaps as a result of variable
thresholds for both processes, or as a result of a cellular
decision between the two responses that may be linked to
a mutual inhibition of the two phenomena. Furthermore,
autophagic cell death occurs under physiological condi-
tions during development and is controlled by similar
mechanisms as autophagy in cell survival. The role of
autophagy is context dependent, as it participates in cell
death under some circumstances and promotes cell sur-
vival in others [18]. However, if we consider that
autophagy is simply a catabolic process that provides
energy and resources to many cellular and biological proc-
esses, this dichotomy can be resolved.
Autophagy has been observed in cancer cell lines as a reac-
tion toward a variety of metabolic and therapeutic stresses
including interruption of growth factor signaling path-
way, activation of mitogen-activated protein kinase sign-
aling, inhibition of proteasomal degradation, the
accumulation of intracellular calcium, and endoplasmic
reticulum stress. However, it is a reversible phenomenon.
When the stress is removed, the autophagic response is
down-regulated. This is quite different from other stress
fates like apoptosis or necrosis that once triggered, are irre-
versible. The increased ROS production may be the link
between signal transduction events and the enzymatic
activation of autophagy genes [16]. The autophagic vesi-
cles form around damaged mitochondria and protein
once activated. The double-membrane vesicle fuses with
the lysosome to degrade the included contents. When the
autophagy persists, the continued depletion of organelles
and critical proteins in the cell will lead to a caspase-inde-
pendent form of cell death. However, for cells undergoing
persistent autophagy, hallmarks of apoptosis like caspase
activation, necrotic cell death, organellar swelling, and
plasma membrane rupture can often be observed. ThisJournal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
Page 4 of 12
(page number not for citation purposes)
makes it complex and difficult to characterize which pre-
dominant mode of cell death is responsible for a popula-
tion of tumor cells. Furthermore, different situations have
been reported. Apoptosis occurs after inhibition of
autophagy. Tumor cell lines use autophagy to recycle
essential metabolites such as lipids and amino acids for
fuelling the bioenergetic machinery in response to the
starvation stress, but the inhibition of autophagy will
cause an accelerated cell death with apoptotic characteris-
tics [19]. The inhibition of autophagy that leads to apop-
tosis may be the result of the failure to adapt to stress. In
another situation, autophagy can delay or suppress the
apoptosis. The chemotherapy drug, cisplatin can induce
apoptosis as an effect of its cytotoxicity. However, it also
simultaneously bears autophagy induction as an immedi-
ate response as cell exposure to the cisplatin. Inhibition of
cisplatin-induced autophagy will block the formation of
autophagosomes and enhance cisplatin-induced apopto-
sis. The switch from autophagy to apoptosis by
autophagic inhibitors indicates that autophagy induction
was responsible for a pre-apoptotic lag phase for cisplatin.
The cisplatin-induced autophagy can be considered as an
adaptive response that suppresses and delays apoptosis
[20]. In contrast, autophagy is induced when apoptosis is
inhibited, and the topoisomerase-2 inhibitor or etoposide
would induce autophagic cell death in the absence of BAX
and BAK [21]. The removal or functional inhibition of
essential proteins from the apoptotic machinery can
switch a cellular stress response from the apoptotic default
pathway to massive autophagy. Autophagy can be
induced by cytotoxic chemotherapy, radiation, or kinase
inhibitors that disrupt growth factor signaling used in can-
cer therapy. The autophagic process can ultimately lead to
programmed cell death if the stress imposed is sustained.
Autophagy emerging as new target for cancer therapy
Autophagy plays a protective role in maintaining energy
homeostasis and protein and organelle quality control for
normal cells. But for cancer cells, it becomes crucial
because cancer cells demand high energy for their contin-
uing uncontrolled proliferation. Autophagy functions are
particularly important under metabolic stress condition.
Any defects in the autophagy mechanism may lead to the
accumulation of cellular damage and generation of
genome instability, thus prompting tumor initiation and
driving cell-autonomous tumor progression. On the other
hand, defects in autophagy will also impair the survival of
tumor cells post metabolic stress, resulting in cell death by
necrosis, apoptosis, or inflammation. The cytokines gen-
erated from inflammation may promote tumor growth
and non-autonomous tumor progression. In this sense,
autophagy protects tumor cells from metabolic stress-
induced damage and allows tumor cells to tolerate and
recover from stress. It can be viewed as a tumor suppres-
sion mechanism [22]. If we can identify the molecules or
pathways of autophagy that are required to suppress the
tumorigenesis, and know which human tumor has defi-
cient autophagy, then autophagy can emerge as a new tar-
get for cancer therapy.
Although autophagy is supposed to maintain cellular
metabolism under starvation, remove damaged
organelles under stress, and therefore improve the total
survival capacity of cells, there is also the question of how,
under certain circumstances, autophagy can lead to cell
death. It is not dependent solely on either the cell type or
the stimulus. The level of autophagy might determine the
final outcome, as moderate induction supports cell sur-
vival whereas massive and/or prolonged induction leads
to cell death. The progressive destruction of cytoplasmic
organelles including mitochondria will make autophagy
an effector mechanism of cell death. When a lethal stimu-
lus has reached a threshold which makes cells decide to
die, either apoptosis or autophagic cell death will ensue.
As apoptosis effectors are abundant, this will be the
default pathway in most cases. The autophagic death
pathway will be the alternative, especially when the apop-
totic pathway is inhibited. Furthermore, the formation of
autophagosomes might not be enough, but the formation
of autolysosomes is required for autophagic cell death.
The lysosomal hydrolases that leak into the cytosol might
trigger a lysosomal death pathway. Lysosomes contain
catabolic hydrolases that participate in the digestion of
autophagic materials in acute cell death by altering the lys-
osomal-membrane permeabilization, or in tissue inva-
sion after release into the extracellular space. The release
of cathepsins, other hydrolases, and ROS after lysosomal-
membrane permeabilization can cause mitochondrial
outer-membrane permeabilization and activate caspase,
resulting in classical apoptosis, caspase-independent
apoptosis or necrosis-like death [23].
Cancer displays several altered autophagic processes from
the induction, regulation and formation of autophagic
vesicles, to the fusion and degradation with lysosomes
[24]. Tumor environments contains low levels of oxygen
and nutrients. Tumor cells not only use glycolysis, but
also increase autophagy to fulfill the high energy demand
of proliferation. Several tumor-suppressor genes such as
p53, PTEN, DAPK, p27kip, TSC1/2, DAPK and cancer-
causing oncogenes such as Bcl-2, AKT, PI3K, mTOR are
autophagy stimulators or inhibitors, respectively. A
monoallelic deletion of beclin 1 promotes tumorigenesis,
as shown by the beclin 1+/- mutant mice, which have a high
incidence of spontaneous tumors [25,26]. This suggests
that autophagy is a tumor suppressive mechanism, and
tumor cells are less sensitive toward autophagic induction
compared to normal cells. It is speculated that autophagy
can limit tumor inflammation, mitigate genome damage
and mutation rate upon metabolic stress, or suppressJournal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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tumor growth. Furthermore, cancer associated altered lys-
osomal composition and trafficking might influence the
autophagic process.
The pro-apoptotic drugs are currently the main chemo-
therapeutic agents in cancer therapy, but resistance to
apoptosis is natural and is frequently observed involving
the activation of the PTEN/PI3K/Akt or NF-κB pathway.
The pro-autophagic drugs are an alternative to overcome
the apoptosis-resistant cancers, but a question remains as
to whether autophagy inhibitors or inducers can be used
for future cancer treatment [24,27-29]. Currently no spe-
cific autophagy modulators are available, but several com-
pounds developed for other purposes have profound
effects on autophagy. Tumor cells have evolved to become
apoptosis-resistant and are reliant on autophagy to sur-
vive the metabolic stress. Since many current cancer ther-
apies (angiogenesis and growth factor and receptor
inhibitors) impose metabolic stress, tumor cells may
become more vulnerable due to their high energy con-
sumption and increased glycolysis, so that the autophagy
inhibitor may be particularly useful. Tumor cells with
defective process of apoptosis and autophagy will fail to
tolerate metabolic stress and undergo acute necrotic cell
death. The necrotic cell death will further stimulate
inflammation through the release of high-mobility group
B1 (HMGB1), which will then result in activation of the
innate immune system and a wound-healing response to
become therapeutically useful.
Several chemotherapeutic agents such as arsenic trioxide,
tamoxifen, resveratrol, IFN-γ, and radiation have been
shown to trigger autophagic cell death in various cancer
cell lines, although most of the cell lines are apoptosis-
defective. Therefore, even though autophagy primarily
serves as a pro-survival response in normal cell homeosta-
sis, it might be able to signal cell death in tumor cells.
Drugs or reagents that specifically trigger autophagic cell
death should be well-tolerated due to highly specific kill-
ing of cancer cells. Furthermore, it can also circumvent
apoptosis-resistance. Nevertheless, we are just at the
beginning of understanding the complex interplay of
autophagy and cancer, as well as the tumor-microenviron-
ment interaction and its interface with the immune sys-
tem. Therefore, to be able to distinguish between the
survival-supporting and death-prompting roles of
autophagy becomes increasingly important. The elucida-
tion of the signaling pathways that confer specificity to the
autophagic response downstream of different stimuli will
help us to select the specific and therapeutic drugs or
agents for cancer therapy.
Con A-induced autophagy
Con A can bind to the mannose moiety of cell surface
glycoproteins specifically because the methyl-αD-man-
nopyranoside can block this interaction. This binding will
induce growth inhibition and cell death in a dose- and
time-dependent manner. For tumor cell lines, a high dose
is cytotoxic whereas a low dose is cytostatic. The Con A
sensitivity varies among different cell lines: the IC50 of
Con A for HepG2, CT-26, ML-1, and Huh-7 are 5, 10, 10,
and 20 μg/ml, respectively. But, for lymphocytes, Con A is
a T-cell mitogen at doses of 1–10 μg/ml, while a higher
dose is still cytotoxic. Lymphocytes are more sensitive to
Con A than tumor cell lines probably due to their high
content in mannose- or glucose-containing moiety on the
cell membrane. It was found that bound Con A on the cell
membrane was internalized and accumulated primarily
onto the mitochondria as early as 1 h post treatment, and
gradually increased mitochondria membrane permeabil-
ity change. Some of the endocytosized Con A was then
degraded in the lysosome. The increased mitochondria
membrane permeability would then lead to the treated
cell death with Annexin V-positive, but no DNA ladder or
typical apoptosis was observed. Instead, cell death pro-
ceeded in an autophagic format. The autophagic pathway
characteristics including LC3-II formation, double-layer
vesicles, BNIP3 induction, and acidic vesicular organelle
formation were observed after Con A treatment. The phos-
phorylated AKT was also down-regulated, indicating that
the growth signal of AKT was altered after Con A treat-
ment. With the electronic microscopic observation, a dou-
ble-layer vesicle and many autophagosomes were
detected on the Con A-treated ML-1 cells. The lysosomal
activity as detected by acridine orange staining was
increased, and the long stable COX-IV was decreased,
indicating the increasing activity of lysosomes. However,
the autophagic molecule, beclin-1 was not found to
increase. In the presence of autophagy inhibitor 3-MA, a
class III-PI3K inhibitor which inhibits the pre-autophago-
some formation, the induction of LC3-I and LC3-II forma-
tion and the autophagic cell death were partially
inhibited. However, the pan-caspase inhibitor zVAD-fmk
had no effect on Con A-induced cell death [30].
Using siRNA for beclin-1, ATG 5 or LC3, the LC3-II con-
version induced by Con A was slightly inhibited by beclin-
1 siRNA, but not by ATG 5 siRNA. Although the Con A-
induced cell death was not affected by either beclin-1 or
ATG 5 siRNA, the Con A-induced LC3-II conversion and
cell death were blocked by LC3 siRNA, suggesting that
LC3 plays a major role in Con A-induced cell death. The
siRNA for BNIP3 inhibited both the LC3-II conversion
and cell death. On the other hand, the LC3 siRNA did not
affect the BNIP3 induction, indicating that the mitochon-
dria BNIP3 was upstream of LC3-II. Furthermore, the
siRNA for AIF slightly inhibited the Con A-induced ML-1
cell death, indicating that the AIF nuclear translocation
only partially contributed to the Con A-induced ML-1 cell
death. BNIP3, an adenovirus E1B 19-kDa-interacting pro-Journal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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tein with cell death-inducing property, was detected ear-
lier than the formation of LC3-II. A major function of
BNIP3 is to determine the on/off state of the mitochon-
dria permeability transition pore. It was therefore con-
cluded that the Con A-induction is not a typical or global
autophagic cell death, and only involves the BNIP3-medi-
ated mitochondria autophagy [30].
The Con A-induced autophagy is an autophagic flux. Con
A causes a LC3-II conversion on ML-1 cells and HepG2
cells in a time-dependent manner. Using the GFP-LC3
processing to monitor the delivery of autophagosomal
membranes, it was found that the GFP-LC3 was degraded
in the lysosome to generate free GFP after Con A treat-
ment. There is co-localization of LC3 and LAMP-1, and
the level of LC3-II was increased in the presence of lyso-
somal protease inhibitors (pepstain and E64D). This sug-
gests that Con A causes autophagic flux on hepatocytes,
and a sustained autophagy will lead to cell death.
The anti-hepatoma effect of Con A
The current treatment for hepatoma is not satisfactory, the
major drawback being the common relapse after surgery
or chemotherapy treatment. Several reasons can explain
the deficiency of the hepatoma therapy. In relation to the
anti-tumor immunity in the host, the liver can be consid-
ered as an immunologic organ with unique characteristics
of immune cells especially with respect to regulation. In
the past, the study of immunotherapy to cancer generally
used tumors grown on the mouse back that are more eas-
ily handled and measured. However, this site is not clini-
cally relevant, especially for liver cancer. The liver is a
special organ, with an immunoregulation system which is
distinct from that of either spleen or lymph nodes. We
therefore need an in situ hepatoma model for the evalua-
tion of any anti-tumor reagent, and so a transplantation
hepatoma model was accordingly created [31,32]. The
transplantable hepatoma cells were injected into the
spleen of the syngenic mice, whereupon the tumor cells
first colonized in the spleen and then continue their
migration into the liver to form various tumor nodules.
The pattern and kinetics of the tumor growth are predict-
able, for example, a transplantation of 1 × 106 ML-1 cells
will generate tumor nodules in the liver, reaching 150–
200 tumor nodules of varying sizes (<1 mm, 1–4 mm, >4
mm in diameter) at three weeks post transplantation. The
tumor nodule growth is time-dependent, and the
hepatoma-bearing mice will die at around day 40 due to
overgrowth of tumors. Many variables can be manipu-
lated, for example, the number of hepatoma cells inocu-
lated can be adjusted for different sizes of tumor nodules
or survival of the tumor-bearing mice. The treatment can
be commenced at any time depending on the tumor load.
Con A is known to be a T cell mitogen and has been
shown to induce hepatitis in mice through the triggering
of NK T cells and subsequent activation of CD4+ T cells
[33,34]. Using our in situ hepatoma model, Con A (7.5
mg/kg body weight, twice at three-day interval) adminis-
tered at one week post transplantation will significantly
decrease 150 tumor nodules in the control mice to 40
tumor nodules in the Con A-treated group at 30 days post
tumor injection. Around 30 – 40% of the mice were
tumor-free. In the survival experiment, the survival of the
hepatoma-bearing mice was prolonged from 40 to 70
days after Con A treatment, while 20–30% of the mice
were cured. Because repeated injections will desensitize
the Con A effect and will generate the anti-Con A anti-
body, it was given only twice at day 7 and 10, and as a
result, the residue tumors would continue growing and
kill the non-tumor-free mice. When the dose of Con A and
the number of injections were increased, for example to
20 mg/kg and 4 times, the liver tumor nodules could be
completely eradicated. The Con A-activated lymphocytes
would infiltrate into the liver to kill the hepatoma cells.
However, there was no apparent hepatocyte damage at the
sub-optimal dose used of 7.5 mg/kg, and the serum
alanine transaminase was not elevated during the treat-
ment course. Con A seems to be less cytotoxic to normal
hepatocytes in tumor-bearing mice than in naïve mice,
probably because the tumor cells sequester more Con A
than normal hepatocytes. Indeed, most of the infiltrating
lymphocytes were found to be present around the liver
tumor nodule post Con A injection with histological tis-
sue staining observation. The therapeutic effect of Con A
can be extended to a large tumor burden. For mice that
have hepatoma growth for 2 or 3 weeks, Con A only par-
tially inhibited the tumor nodule growth and prolong the
mouse survival. The Con A therapeutic effect decreased
along with the increased tumor load. The cells participat-
ing in this inhibition were further demonstrated to be
CD8+ T as indicated by the in vivo depletion of CD4+ or
CD8+ T cells. Depletion of CD8+ T cells blocked the anti-
tumor effect of Con A whereas depletion of CD4+ T cells
also partially affected the Con A anti-tumor activity. How-
ever, in the control group, the CD4+ T depletion could par-
tially inhibit the tumor formation in the PBS-treated
group, indicating that some regulatory CD4+ T might also
participate in the anti-hepatoma activity of the liver. Fur-
thermore, the in vivo direct effect of Con A is demon-
strated in severe combined immune deficiency (SCID)
mice. Con A at a high dose of 20 mg/kg can partially
inhibit the liver tumor formation in SCID mice at 21 days
post tumor inoculation. This indicates that Con A has a
direct inhibitory effect on liver tumor nodule formation
independently of lymphocyte activation. Interestingly,
during the eradication of established hepatoma in the
liver, the ML-1 tumor-specific immunities were estab-
lished and could prevent the next tumor formation. The
tumor-free mice after Con A treatment were inoculated
subcutaneously with either ML-1 or CT-26 cells dorsally,
and the ML-1 cells could no longer grow in ML-1-sensi-Journal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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tized mice compared with naïve mice, but CT-26 tumor
cells did grow. This suggests that during the Con A-
induced eradication of hepatoma, an immune memory
was generated and can lead to resistance to further chal-
lenge of the same tumor [30].
How the Con A exerts its anti-hepatoma effect is intrigu-
ing. The liver, in its function as a filtering organ, can trap
blood-born foreign substances, and its anatomic location
and unique blood circulation makes it a good site to con-
centrate and bind Con A. In our in situ hepatoma model,
Con A trapped in the liver would preferentially bind to
hepatoma cells through its specific binding to the high
content of mannose residue on tumor cell membranes.
We reasoned that the Con A which accumulated in the
liver nodules not only directly induces hepatoma cells to
undergo autophagic cell death, but also activates and
recruits blood-born lymphocytes into the liver. This
hepatic inflammation subsequently induces the adaptive
immune response against the tumor and leads to liver
tumor regression. The Kupffer, NK, NKT, CD4+ T, and
CD8+ T cells are activated, but CD8+ T cells are the major
effector cells to kill the tumor cells, whereas the CD4+ T
cells have an effector function as well as a regulatory func-
tion. Initially, the Con A effect is not tumor cell-specific,
but as hepatic inflammation proceeds following Con A-
mediated destruction and activation, tumor antigens of
the hepatoma cells will be processed and presented to the
tumor antigen-specific CD4+ T and CD8+ T cells. Tumor-
specific immunity is established thereafter. Either profes-
sional macrophages or non-professional epithelial cells
can phagocytose the dying autophagic cells [35]. It would
be interesting to know how the liver Kupffer cells or den-
dritic cells handle the autophagic hepatoma cells exoge-
nously and present hepatoma cell antigen to CD4+ T and
CD8+ T cells in both MHC class II and class I-restricted
mechanisms. Con A can stimulate macrophages to up-reg-
ulate the TLRs and enhance the cytokine production [36].
The lymphocytes/monocytes are found to be more sensi-
tive to Con A than tumor cells due to their high content of
mannose-containing moiety on the cell membrane. Con
A at a dose of 1–10 μg/ml is mitogenic, but becomes cyto-
toxic at dose higher than 40 μg/ml. T cells are reported to
undergo autophagy for their death, survival and prolifera-
tion [37,38]. Con A can also induce the LC3-II conversion
in lymphocytes. The signal pathways are apparently differ-
ent because the outcomes (mitogenic or autophagic) are
distinct. Therefore, the integration or cross-regulation for
Con A on different cells or different dosages needs further
investigation, and the effect of Con A on the immune sys-
tem also needs re-evaluation. The autophagic vesicle has
recently been shown to participate in the antigen delivery
for MHC class II antigen presentation of the cytoplasmic
proteins [39,40].
Alternatively, the anti-tumor effect of Con A may be medi-
ated by the NK cells because Miyagi T et al. reported that
Con A can activate the intrahepatic innate immune cells to
provoke an antitumor effect in a NK cell- and IFN-γ-
dependent manner in a CT-26 hepatic metastasis model
[41]. This observation is distinct from ours, and the dose
of Con A used and the immune mechanism involved are
different. A non-hepatocytotoxic dose of Con A (2 mg/kg)
was used for the purpose of avoiding liver damage, the
intra-hepatic NK cells were activated, and the innate
immunity with IFN-γ production participated in the pre-
vention of tumor growth in the liver. In contrast, we used
a high dose of Con A (hepato-cytotoxic to hepatocytes in
naïve mice) and activated the CD8+ T cells to participate in
the inhibition of the established liver tumor. Of course
the activation of the NK cells is not excluded in our sys-
tem.
Chemoprevention of Con A
Many dietary lectins are resistant to digestion, and were
shown to be toxic to animals upon oral ingestion presum-
ably because of the intestinal damage after binding to the
cells lining the intestinal mucosa. An appreciable portion
of the endocytosed lectin can be transported across the gut
wall into the systemic circulation. Lectins may therefore
be responsible for reported cases of human intoxication
associated with the consumption of inadequately cooked
beans [42]. Historically, Mistletoe (the galactoside-spe-
cific lectin from Viscum album) has been introduced for
alternative treatment of cancer for a long time in Europe.
Extracts from the plant are used in adjuvant cancer ther-
apy as injections. The interest in using the potential health
benefits of bioactive polypeptides and proteins derived
from soybeans, including lunasin and lectins has
increased. Soybeans have been reported to contain a vari-
ety of anticarcinogenic phytochemicals. There has also
been increased interest in the potential health benefits of
bioactive polypeptides and proteins from soybeans,
including lunasin and lectins [43,44]. We have observed
that orally-fed Con A also inhibited liver nodule forma-
tion in our system, and this is intriguing because it might
open a new field for chemopreventive treatment in cancer.
Natural Con A-like substances that possess both immu-
nomodulating and autophagy-inducing activities, espe-
cially in edible vegetable plants, seeds or health food, can
be screened and tested for potential use as chemopreven-
tive agents for cancer.
Lectin immunotherapy versus tumor antigen-specific 
cancer vaccine
Cancer immunotherapy with tumor-associated antigens
has been debated recently. In 2004, Rosenberg et al.
reported a low objective response rate (2.6%) in 440
patients with cancer vaccine trials. The current active
immunization with specific antigens has limitations or isJournal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
Page 8 of 12
(page number not for citation purposes)
not effective, and so needs to be re-evaluated [45,46].
Alternative strategies that can mediate cancer regression in
preclinical and clinical models are urgently needed. Can-
cer vaccines constitute a dynamic process involving the
host's immune response. A dynamic balance occurs
between the induction and maintenance of host immune
response and host/tumor factors that have the potential to
diminish these responses. The tumor-specific immunity is
considered to be an "autoimmunity" response because
most tumor-associated antigens are self antigens. The host
immune system is strictly regulated by the immune sup-
pressive modalities to suppress the immune responses to
"self antigen". The balance of immune-enhancing versus
immune-suppressive factors comes into play in the cancer
vaccine therapy. Tumor-induced expansion of regulatory
T cells has become an obstacle to successful cancer immu-
notherapy, as inactivation of T regulatory cells is crucial
for a successful immunotherapy [47]. However, it is diffi-
cult to achieve the therapeutic effect by a single therapy,
even with multiple doses of vaccine to boost the immune
response and memory. The combination of therapies is
therefore becoming a new paradigm. Several strategies are
employed for the combination therapy [48]. For example,
vaccine therapy can be enhanced by biological adjuvants
such as cytokines, danger signals, or immune inhibitors.
Multiple vaccine therapies are employed for the sake of
minimizing the toxicity, where prime/boost regimens or
virus vector deliveries are used. The tumor cells are altered
by drugs or radiation to become more susceptible to T-
cell-mediated lysis. Moreover, vaccines initiate a dynamic
process, so that anti-tumor effects are potentiated by sub-
sequent therapies, and vaccine therapy can be combined
with chemotherapy to be more effective.
To stimulate an anti-tumor immune response, the tumor
cells have to be immunogenic. During tumor cell death,
apoptosis is an immunologically silent type of cell death
whereas necrosis is immunogenic and will stimulate an
inflammatory immune response [49,50]. The immune
response elicited by tumor cells that spontaneously
undergo apoptosis will abort incipient tumors during
immunesurveillance. On the other hand, immune
responses triggered by treatment-induced tumor immu-
nogenic cell deaths will contribute to the therapeutic effi-
cacy of chemotherapy or radiotherapy. Necrosis is a form
of cell death with an unregulated or unscheduled process.
The disruption of plasma membrane that is characteristic
of necrotic cell death will spill the intracellular proteins
that subsequently activate a damage response from the
host immune system. The brisk inflammatory response
and immune amplification of the damage signal is in con-
trast to apoptotic cells that are silently removed by macro-
phages. A rapid loss of cellular membrane potential is a
key feature of necrosis. The necrosis can result from mito-
chondrial depolarization, cellular energy depletion, dis-
turbance of Ca2+  homeostasis, activation of PARP,
activation of nonapoptotic protease, generation of ROS,
and disruption of plasma membrane. All of these events
are inter-related and cross-regulated. Energy failure is the
major cause of necrosis. In the cells with deficiencies in
the apoptotic mechanism, the cells become susceptible to
necrosis induction. The key mediator for the necrosis is
poly(ADP-ribose) polymerase, a nuclear protein activated
by DNA damage, which can rapidly deplete the cell of
NAD+, the essential cofactor for aerobic glycolysis. This
imposes a transient inhibition of glycolysis and inhibition
of ATP production. The bioenergetic crisis that occurs with
acute NAD+ and ATP depletion in glycolytic cells is associ-
ated with the accumulation of high concentrations of
intracellular calcium and ROS, which in turn cooperate to
activate calpains, phospholipase A2, and the lysosomes
were permeabilized to leak the cathepsins. Proteolysis and
lipid peroxidation cause wide-spread membrane permea-
bilization and irreversible necrotic cell death [51].
Immune responses in the presence of autophagic cell 
death
Conventional cancer therapies target to cell death via
apoptosis, necrosis, mitotic catastrophe, autophagy, and
senescence [52]. Each has its own characteristics, and the
nature of the host's immune response to these tumor cell
deaths is distinct among different stress conditions. Apop-
totic cells are cleared by either professional (macrophages
or immature dendritic cells) or non-professional phago-
cytes (fibroblasts, endothelial, epithelial cells). The expo-
sure of the phosphatidylserine and calreticulin on the
surface of the apoptotic cells is recognized by the LDL-
receptor-related protein on phagocytes, and this results in
the engulfment of the apoptotic cells and the suppression
of the pro-inflammatory cytokines [53,54]. In most cases,
apoptosis is an immune-silent form of cell death. The
TGF-β released from the dying cells or the macrophage
that ingested apoptotic cells will suppress the pro-inflam-
matory cytokine production. For the immature dendritic
cells, the IL-12 that is important for the T cell activation
will be suppressed, and the dendritic cells become toler-
genic. On the other hand, necrosis is always an inflamma-
tory cell death. The HMGB1 is normally a nuclear protein
that is passively released in the microenvironment by
necrotic cells. Its binding to the RAGE receptor and Toll-
like receptor on macrophages or dendritic cells will stim-
ulate the secretion of pro-inflammatory cytokines.
HMGB1 is an endogenous immune adjuvant released by
necrotic cells that promotes the migration and maturation
of dendritic cells, and T cell activation [55,56]. Further-
more, the necrosis-induced recruitment of macrophage
and T cells and the subsequent macrophage-associated
production of angiogenic and growth factors will further
accelerate the chronic inflammation and tumorigenesis.Journal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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The role of autophagy that participates in both innate and
adaptive immunity has recently begun to be revealed.
Autophagy is not only a cellular response to restrict viral
infections and replication of intracellular bacteria and
parasites, but also participates in the MHC class II presen-
tation [57,58]. The antigen presentation by major histo-
compatibility complex (MHC) molecules that are
subsequently recognized by CD4+ T and CD8+ T lym-
phocytes is critical to elicit an appropriate immune
response. The traditional view of CD8+ T lymphocytes
interaction with MHC class I molecules that present
endogenous antigens (9–11 amino acids) of cytosolic and
nuclear origin is processed by the ubiquitinated proteas-
ome degradation system. Whereas MHC class II antigenic
peptides which are products of lysosomal degradation are
presented to CD4+ T lymphocytes. The two main protein
degradation machineries in eukaryotic cells are in charge
of different forms of antigen presentation. Peptides gener-
ated by the proteasome are presented on MHC class I
products, whereas products of lysosomal degradation are
displayed on MHC class II. However, a recent study indi-
cates that MHC II ligands can also be of endogenous ori-
gin and that the autophagy is the conduit for intracellular
antigen access to MHC II processing during its delivery of
the autolysosome to the MHC-class-II-loading compart-
ment (MIIC). This provides a cross-presentation for the
endogenous protein to an additional class II presentation
to CD4+ T cells. In addition to the participation in the
antigen presentation, autophagy also plays a role in the
survival and death of T cells. Since CD4+ T cells can be acti-
vated with the autophagic delivery of intracellular protein
for class II presentation, they will certainly contribute to
CD4+ T cell immune surveillance of infected and trans-
formed cells. Self-antigen presentation on MHC class II of
both thymic epithelial cells and dendritic cells induces
central and peripheral tolerance in the CD4+ T cell com-
partment [59]. Dendritic cells, NK, and T cells can induce
autophagy in the infected cells to fight infections, but at
the same time the fate of these effector cells is also deter-
mined by their own capacity to perform autophagy. Atg 5
deficiency leads to decreased T and B cell numbers in
mice, and the Atg 5 deficient CD4+ and CD8+ T cells fail to
undergo efficient proliferation upon T cell receptor stimu-
lation [37]. Th2 polarized CD4+ T cells were reported to be
The molecular mechanism of Con A anti-hepatoma effect Figure 1
The molecular mechanism of Con A anti-hepatoma effect.Journal of Biomedical Science 2009, 16:10 http://www.jbiomedsci.com/content/16/1/10
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more susceptible to autophagic cell death [38].
Autophagy seems to play a role in T cell maintenance dur-
ing the steady state and after activation. All these data sug-
gest that autophagy-mediated intracellular antigen
presentation not only broadens the MHC class II presen-
tation, and enables the immune surveillance and toler-
ance induction, but also regulates the T cell survival and
death. This provides us an opportunity to manipulate the
autophagy to enhance the pathogen clearance as well as
modulate the anti-tumor immune responses.
Chemotherapy remains the treatment modality of choice
for most advanced cancer while immunotherapy is at the
infant stage of cancer treatment. The two are regarded as
either unrelated or sometimes antagonistic. However, it
has become clear that the chemotherapy-induced tumor
cell death process will engage with the anti-tumor
immune response, and that the two modalities can be syn-
ergistically beneficial for cancer treatment [60-64]. The
best strategy of immunotherapy will be the association of
both a direct cytotoxic drug effect and an indirect
immune-mediated cytotoxic effect. The generation of an
immunogenic tumor cell death through the induction of
calreticulin, HSP, release of inflammatory mediators,
proinflammatory cytokines or HMGB1 will favor the rec-
ognition of tumor cell antigens by DC, NK, and T cells.
The Con A-induced autophagic cell death with necrosis
can initiate a tumor cell-specific immune response, but
although Con A can initiate the immune response in a
tumor cell in a non-specific manner at the beginning, a
tumor-specific immune induction occurs during the erad-
ication of tumor cells, which then leads to a tumor-cell
specific response during the later stage. In this sense, Con
A is a novel type of endogenous cancer vaccine immuno-
therapy. The combination effect of direct autophagic
induction on target cells and indirect immunomodulating
activity on lymphocytes via the mannose/glucose binding
to tumor cells will induce an in situ inflammatory
response and the subsequent anti-tumor response.
Conclusion: Lectin of Con A is a potential anti-hepatoma 
agent
Lectins are emerging as bioactive plant proteins to be used
in biomedicine, especially for the potential cancer treat-
ment [65-67]. Several lectins have been found to possess
anti-cancer properties; they are used as therapeutic agents,
preferentially binding to cancer cell membrane, causing
cytotoxicity via inducing apoptosis, autophagy, or necro-
sis, and inhibiting the tumor growth. Furthermore, they
could simultaneously activate the immune system, stimu-
late the cytokine production inside the tumor mass, and
the recruited lymphocytes will then participate in the
eradication of the tumor. Con A is a prototype of lectins
to have this anti-hepatoma effect [68]. We have found that
other lectins of Pisum Sativum Agglutinin (PSA) and Lens
Culinaris Agglutinin (LCA) from Pisum sativum and Lens
culinaris that specifically bind glucose and mannose also
have anti-hepatoma effect. Like Con A, PSA and LCA
could also cause hepatoma cell death and are mitogenic to
lymphocytes. Both PSA and LCA could significantly
inhibit ML-1 liver tumor nodule formation in BALB/c
mice. The dual-characteristic of lectins like Con A, spring-
ing from their carbohydrate-specific binding, to exhibit
both immunomodulating and autophagy-inducing activ-
ity, will make them potential candidates for successful
anti-hepatoma agents. A cartoon is shown in Figure 1 for
its mechanism of anti-hepatoma activity. Moreover, this
discovery will open a new area of exploration for natural
lectins as anti-cancer compounds.
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